title: Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation.
abstract: BACKGROUND
  To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation.
  
  
  METHODS
  Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4-13 months).
  
  
  RESULTS
  All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1-6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.
authors.affiliation: Department of Ophthalmology, National Taiwan University Hospital and School of Medicine, National Taiwan University, 7, Chung Shan South Rd., Taipei, Taiwan.
authors.forename: Chih-Wei
authors.initials: CW
authors.lastname: Shih
authors.forename: Chung-May
authors.initials: CM
authors.lastname: Yang
authors.forename: Muh-Shy
authors.initials: MS
authors.lastname: Chen
authors.forename: Tsung-Jen
authors.initials: TJ
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D049109:Cell Proliferation / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005355:Fibrosis; D005654:Fundus Oculi; D005740:Gases / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D012166:Retinal Hemorrhage / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D012171:Retinal Vessels / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005740:Gases; D000068258:Bevacizumab